MY130792A - 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES - Google Patents
17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASESInfo
- Publication number
- MY130792A MY130792A MYPI20034363A MYPI20034363A MY130792A MY 130792 A MY130792 A MY 130792A MY PI20034363 A MYPI20034363 A MY PI20034363A MY PI20034363 A MYPI20034363 A MY PI20034363A MY 130792 A MY130792 A MY 130792A
- Authority
- MY
- Malaysia
- Prior art keywords
- hydroxysteroid dehydrogenase
- inhibitors
- treatment
- compounds
- dependent diseases
- Prior art date
Links
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 title abstract 3
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000003098 androgen Substances 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42726302P | 2002-11-18 | 2002-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY130792A true MY130792A (en) | 2007-07-31 |
Family
ID=32326512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20034363A MY130792A (en) | 2002-11-18 | 2003-11-14 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7074795B2 (https=) |
| EP (1) | EP1562901B1 (https=) |
| JP (2) | JP4614770B2 (https=) |
| CN (1) | CN100374421C (https=) |
| AR (1) | AR042046A1 (https=) |
| AT (1) | ATE469886T1 (https=) |
| AU (1) | AU2003290799A1 (https=) |
| CA (1) | CA2506290C (https=) |
| CL (1) | CL2003002356A1 (https=) |
| DE (1) | DE60332862D1 (https=) |
| ES (1) | ES2345146T3 (https=) |
| MX (1) | MXPA05005360A (https=) |
| MY (1) | MY130792A (https=) |
| PE (1) | PE20040750A1 (https=) |
| TW (1) | TW200412964A (https=) |
| WO (1) | WO2004046111A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60323765D1 (de) | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| US7851474B2 (en) * | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
| CN106890100A (zh) * | 2011-04-25 | 2017-06-27 | 朴俊炯 | 用于预防脱发和促进毛发生长的局部施用的组合物 |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6556125B2 (ja) | 2013-06-25 | 2019-08-07 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| JP6532599B2 (ja) | 2015-09-02 | 2019-06-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド |
| HRP20240679T1 (hr) | 2017-06-08 | 2024-08-16 | Organon R&D Finland Ltd | 17-oksimi 15.beta.-[3-propanamido]-supstituiranih etera-1,3,5(10)-trien-17-ona za uporabu u inhibiciji 17.beta.-hidroksisteroid dehidrogenaza |
| AU2018386327B2 (en) * | 2017-12-15 | 2023-04-13 | Inthera Bioscience AG | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |
| JP7417608B2 (ja) | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 |
| EP4168014A1 (en) | 2020-06-19 | 2023-04-26 | Inthera Bioscience AG | Oxopiperazine derivatives for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58836B1 (en) | 1984-08-02 | 1993-11-17 | Labrie Fernand | Pharmaceutical composition for combination therapy of hormone dependent cancers |
| ZA901847B (en) | 1989-03-10 | 1991-10-30 | Endorecherche Inc | Combination therapy for the treatment of estrogen sensitive diseases |
| ATE230994T1 (de) | 1989-07-07 | 2003-02-15 | Endorech Inc | Methode zur behandlung androgenbedingter krankheiten |
| DE69034148T2 (de) | 1989-07-07 | 2005-06-30 | Endorecherche Inc., Ste-Foy | Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| ATE197458T1 (de) | 1993-05-17 | 2000-11-11 | Endorech Inc | Verbesserte antiandrogene |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| AU4801197A (en) * | 1996-09-13 | 1998-04-02 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors |
| HUP0101809A3 (en) * | 1998-03-11 | 2002-07-29 | Endorech Inc Sainte Foy | Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use |
| PE20030703A1 (es) | 2001-09-06 | 2003-08-21 | Schering Corp | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 |
| EP1436281B1 (en) * | 2001-10-17 | 2010-06-16 | Schering Corporation | Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
-
2003
- 2003-11-14 WO PCT/US2003/036203 patent/WO2004046111A1/en not_active Ceased
- 2003-11-14 DE DE60332862T patent/DE60332862D1/de not_active Expired - Lifetime
- 2003-11-14 TW TW092131992A patent/TW200412964A/zh unknown
- 2003-11-14 AT AT03783382T patent/ATE469886T1/de not_active IP Right Cessation
- 2003-11-14 CN CNB2003801086673A patent/CN100374421C/zh not_active Expired - Fee Related
- 2003-11-14 JP JP2004553612A patent/JP4614770B2/ja not_active Expired - Fee Related
- 2003-11-14 AR ARP030104210A patent/AR042046A1/es unknown
- 2003-11-14 AU AU2003290799A patent/AU2003290799A1/en not_active Abandoned
- 2003-11-14 US US10/713,828 patent/US7074795B2/en not_active Expired - Fee Related
- 2003-11-14 CA CA2506290A patent/CA2506290C/en not_active Expired - Fee Related
- 2003-11-14 MX MXPA05005360A patent/MXPA05005360A/es active IP Right Grant
- 2003-11-14 PE PE2003001156A patent/PE20040750A1/es not_active Application Discontinuation
- 2003-11-14 CL CL200302356A patent/CL2003002356A1/es unknown
- 2003-11-14 MY MYPI20034363A patent/MY130792A/en unknown
- 2003-11-14 ES ES03783382T patent/ES2345146T3/es not_active Expired - Lifetime
- 2003-11-14 EP EP03783382A patent/EP1562901B1/en not_active Expired - Lifetime
-
2006
- 2006-02-24 US US11/362,217 patent/US7476681B2/en not_active Expired - Fee Related
-
2010
- 2010-03-15 JP JP2010058356A patent/JP2010138204A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2506290C (en) | 2012-04-24 |
| CA2506290A1 (en) | 2004-06-03 |
| CN1738800A (zh) | 2006-02-22 |
| AR042046A1 (es) | 2005-06-08 |
| CN100374421C (zh) | 2008-03-12 |
| JP2010138204A (ja) | 2010-06-24 |
| US7476681B2 (en) | 2009-01-13 |
| AU2003290799A1 (en) | 2004-06-15 |
| US20040127503A1 (en) | 2004-07-01 |
| WO2004046111A1 (en) | 2004-06-03 |
| US7074795B2 (en) | 2006-07-11 |
| ATE469886T1 (de) | 2010-06-15 |
| CL2003002356A1 (es) | 2005-02-11 |
| TW200412964A (en) | 2004-08-01 |
| EP1562901B1 (en) | 2010-06-02 |
| DE60332862D1 (de) | 2010-07-15 |
| US20060148816A1 (en) | 2006-07-06 |
| PE20040750A1 (es) | 2004-11-06 |
| JP2006513169A (ja) | 2006-04-20 |
| JP4614770B2 (ja) | 2011-01-19 |
| HK1073313A1 (en) | 2005-09-30 |
| EP1562901A1 (en) | 2005-08-17 |
| ES2345146T3 (es) | 2010-09-16 |
| MXPA05005360A (es) | 2005-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003293555A1 (en) | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| IL161154A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| EP2261236A3 (en) | Composition for proteasome inhibition | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| BG104780A (en) | Inhibitors of phospholipase enzymes | |
| MXPA03004832A (es) | Compuestos y sus usos. | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2005041924A3 (en) | Administration of levodopa and carbidopa | |
| AR020345A1 (es) | Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones. | |
| MXPA02011632A (es) | Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1. | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| PT1509232E (pt) | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| GEP20074030B (en) | Controlled synthesis of ziprasidone and compositions thereof | |
| MY134480A (en) | 4-pyrrolidino-phenyl-benzyl ether derivatives | |
| AU2003228674A1 (en) | Muscarinic antagonists | |
| TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
| TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
| AU2003294785A1 (en) | Hair treatment compositions | |
| WO2004052236A3 (en) | Methods and compositions for treatment of otitis media |